Insilico Medicine, an artificial intelligence-driven drug discovery startup, added $35 million in Series D2 funding led by Prosperity7 Ventures, bringing the Series D total to $95 million. The company, which has offices in Hong Kong and New York, said it raised the initial Series D tranche in June from investors including BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, Deerfield, BOLD Capital Partners and Pavilion Capital.
Prellis Biologics Inc., a San Francisco-based startup utilizing its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro, raised $35 million in Series C funding. Co-led by Celesta Capital and Avidity Partners, the round included participation from Khosla Ventures, SOSV, True Ventures and Lucas Venture Group. In addition to the investment, the company appointed Michael Nohaile to the post of chief executive, replacing founder Melanie Matheu, who will assume the role of chief technology officer. Mr. Nohaile joins Prellis Biologics from Generate Biomedicines. James Rothman and Avidity Partners’ Lei Meng will join the company’s board.
Evidence Partners Inc., a Canada-based literature review automation software company for healthcare and healthtech companies, closed a $20 million growth financing round. Thomvest Ventures led the investment, which included contributions from Pender Ventures and Export Development Canada.
Biofourmis Inc., a Boston-based startup seeking to use digital technologies to improve patient outcomes and help hospitals run more efficiently, added $20 million in Series D financing from Intel Capital, bringing the round total to $320 million. The company said it raised the initial $300 million tranche back in April. Additional investors in the company include General Atlantic, CVS Health, SoftBank Vision Fund 2, Openspace Ventures, Mass Mutual Ventures, Sequoia Capital and EDBI.
Maximus Inc., a Los Angeles-based startup that uses prescription medication and health coaching to optimize testosterone levels, has secured $15 million in funding led by Keith Rabois at Founders Fund. Additional investors in the company include 8VC, Abstract Ventures, 10X Capital, Unshackled Ventures, OneVC, Gaingels, Correlation Ventures, Chamaeleon, Rational Ventures, What If Ventures, Shrug Capital and Electric Ant.
Abridge, a Pittsburgh-based startup using artificial intelligence to summarize and structure health conversations, landed $12.5 million in Series A1 funding. Lead investor Wittington Ventures was joined by Union Square Ventures, Bessemer Venture Partners, Pillar Venture Capital, UPMC Enterprises and others in the round.
Salvo Health, a New York-based virtual health clinic focusing on specialty care for chronic gut conditions, completed a $10.5 million seed round from investors including Threshold Ventures, Torch Capital and Felicis.
Nanopath Inc., a Cambridge, Mass.-based women's health startup, snagged a $10 million Series A round. Co-led by Norwest Venture Partners and SV Health Investors’ Medtech Convergence Fund, the investment included additional support from Gingerbread Capital and Green D Ventures. Norwest Venture Partners’ Jeff Crowe and SV Health Investors' Aaron Sandoski joined the Nanopath board.
|